Talkmed Group Ltd
SGX:5G3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Talkmed Group Ltd
Revenue
Talkmed Group Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Talkmed Group Ltd
SGX:5G3
|
Revenue
S$78.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Cordlife Group Ltd
SGX:P8A
|
Revenue
S$38.9m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Q & M Dental Group (Singapore) Ltd
SGX:QC7
|
Revenue
S$197.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
A
|
Aoxin Q & M Dental Group Ltd
SGX:1D4
|
Revenue
¥171m
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
HC Surgical Specialists Ltd
SGX:1B1
|
Revenue
S$18.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
EUDA Health Holdings Ltd
NASDAQ:EUDA
|
Revenue
$4m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Talkmed Group Ltd
Glance View
TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. The firm is a provider of medical oncology and palliative care health care services in Singapore. The firm operates through two segments: Oncology services, and Cellular and gene therapy related products and services. The Oncology services provide specialist doctors and clinical staff to Parkway Cancer Centre (PCC), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services (consultancy services). The company also provides consultancy services to Thu Cuc International General Hospital (TCH), to enable TCH to operate a medical center for the provision of oncology services in Hanoi, Vietnam. The company also provides consultancy services to the patients in Beijing and Chongqing. Cellular and gene therapy-related products and services include the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd. (CellVec).
See Also
What is Talkmed Group Ltd's Revenue?
Revenue
78.2m
SGD
Based on the financial report for Dec 31, 2024, Talkmed Group Ltd's Revenue amounts to 78.2m SGD.
What is Talkmed Group Ltd's Revenue growth rate?
Revenue CAGR 10Y
2%
Over the last year, the Revenue growth was -7%. The average annual Revenue growth rates for Talkmed Group Ltd have been 9% over the past three years , 1% over the past five years , and 2% over the past ten years .
